Sample size determination in clinical trials with multiple co-primary binary endpoints

被引:46
作者
Sozu, Takashi [1 ,2 ]
Sugimoto, Tomoyuki [2 ]
Hamasaki, Toshimitsu [1 ,2 ]
机构
[1] Osaka Univ, Ctr Adv Med Engn & Informat, Suita, Osaka 5650871, Japan
[2] Osaka Univ, Dept Biomed Stat, Grad Sch Med, Suita, Osaka 5650871, Japan
关键词
correlated endpoints; multivariate Bernoulli; association measures; continuity correction; arcsine transformation; Fisher's exact method; EFFICACY; DESIGN; ISSUES; POWER;
D O I
10.1002/sim.3972
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Clinical trials often employ two or more primary efficacy endpoints. One of the major problems in such trials is how to determine a sample size suitable for multiple co-primary correlated endpoints. We provide fundamental formulae for the calculation of power and sample size in order to achieve statistical significance for all the multiple primary endpoints given as binary variables. On the basis of three association measures among primary endpoints, we discuss five methods of power and sample size calculation: the asymptotic normal method with and without continuity correction, the arcsine method with and without continuity correction, and Fisher's exact method. For all five methods, the achieved sample size decreases as the value of association measure increases when the effect sizes among endpoints are approximately equal. In particular, a high positive association has a greater effect on the decrease in the sample size. On the other hand, such a relationship is not very strong when the effect sizes are different. Copyright (C) 2010 John Wiley & Sons, Ltd.
引用
收藏
页码:2169 / 2179
页数:11
相关论文
共 50 条
  • [21] Sample Size Determination for Equivalence Assessment with Multiple Endpoints
    Sun, Anna
    Dong, Xiaoyu
    Tsong, Yi
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2014, 24 (06) : 1203 - 1214
  • [22] Sample size determination and re-estimation for matched pair designs with multiple binary endpoints
    Xu, Jin
    Yu, Menggang
    BIOMETRICAL JOURNAL, 2013, 55 (03) : 430 - 443
  • [23] A logrank test-based method for sizing clinical trials with two co-primary time-to-event endpoints
    Sugimoto, Tomoyuki
    Sozu, Takashi
    Hamasaki, Toshimitsu
    Evans, Scott R.
    BIOSTATISTICS, 2013, 14 (03) : 409 - 421
  • [24] Adaptive group-sequential design with population enrichment in phase 3 randomized controlled trials with two binary co-primary endpoints
    Sinha, Arup K.
    Moye, Lemuel, III
    Piller, Linda B.
    Yamal, Jose-Miguel
    Barcenas, Carlos H.
    Lin, Jianchang
    Davis, Barry R.
    STATISTICS IN MEDICINE, 2019, 38 (21) : 3985 - 3996
  • [25] Optimal Two-Stage Design for the Phase II Cancer Clinical Trials With Responses and Early Progression as Co-primary Endpoints
    Tan, Xianming
    Takahara, Glen
    Tu, Dongsheng
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2010, 2 (03): : 348 - 354
  • [26] Sample size optimization and initial allocation of the significance levels in group sequential trials with multiple endpoints
    Gou, Jiangtao
    BIOMETRICAL JOURNAL, 2022, 64 (02) : 301 - 311
  • [27] Bayesian sample-size determination methods considering both worthwhileness and unpromisingness for exploratory two-arm randomized clinical trials with binary endpoints
    Kakizume, Tomoyuki
    Zhang, Fanghong
    Kawasaki, Yohei
    Daimon, Takashi
    PHARMACEUTICAL STATISTICS, 2020, 19 (01) : 71 - 83
  • [28] Multiplicity Adjustment and Sample Size Calculation in Clinical Trials with Multiple Endpoints: An Industry Survey of Current Practices in Japan
    Sakamaki, Kentaro
    Morita, Yusuke
    Iba, Katsuhiro
    Kamiura, Toshifumi
    Yoshida, Seitaro
    Ogawa, Naoyuki
    Suganami, Hideki
    Tsuchiya, Satoru
    Fukimbara, Satoru
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2020, 54 (05) : 1097 - 1105
  • [29] Selection of composite binary endpoints in clinical trials
    Bofill Roig, Marta
    Gomez Melis, Guadalupe
    BIOMETRICAL JOURNAL, 2018, 60 (02) : 246 - 261
  • [30] Estimation of the binomial probabilities in a two-stage phase II clinical trial with two co-primary endpoints
    Sun, Yiming
    Zhang, Xinyi
    Tan, Xianming
    Tu, Dongsheng
    CONTEMPORARY CLINICAL TRIALS, 2021, 105